A 28-year-old woman with a 4-year history of Crohn's disease (ileocecal involvement, previously well-controlled on azathioprine) presents with a 2-week history of worsening abdominal pain, diarrhea (5–6 stools/day), and a palpable right lower quadrant mass. CT enterography shows a 4 cm segment of ileocecal stricturing with proximal bowel dilatation and no fistulas or abscess. She is afebrile, Hb 10.8 g/dL, CRP 2.1 mg/dL, and albumin 3.2 g/dL. What is the most appropriate next step in management?

Explanation

## Clinical Scenario Analysis This patient presents with **Crohn's disease with fibrostenosing (stricturing) phenotype**: - Ileocecal stricture (4 cm) with proximal dilatation on CT enterography - Chronic, worsening symptoms over 2 weeks - **Minimal systemic inflammation** (afebrile, CRP 2.1 mg/dL — only mildly elevated) - Mild malnutrition (albumin 3.2 g/dL, Hb 10.8 g/dL) - **No fistulas, abscess, or perforation** ### Key Distinction: Inflammatory vs. Fibrostenosing Crohn's Disease | Feature | Inflammatory | Fibrostenosing (Stricturing) | |---------|--------------|------------------------------| | CRP/ESR | Markedly elevated | Normal/mildly elevated | | CT appearance | Mural thickening, enhancement | Stricture, fibrosis, proximal dilatation | | Response to biologics | Good | Poor (fibrosis is irreversible) | | Nutritional support | Adjunctive | Primary therapeutic role | | Surgery | Reserved for failure | Considered after nutritional trial | **High-Yield:** In **fibrostenosing Crohn's disease**, the dominant pathology is **fibrosis and stricturing**, not active mucosal inflammation. Immunosuppressants and biologics target inflammation and are largely ineffective against established fibrosis. ## Management Strategy for Stricturing Crohn's Disease ### Step 1: Optimize Nutrition with EEN **Exclusive Enteral Nutrition (EEN)** is the preferred initial approach for stricturing disease without acute obstruction or sepsis: 1. **Elemental or polymeric formula** — 1500–2000 kcal/day for 6–8 weeks 2. **Mechanism of benefit:** - Reduces intraluminal antigen load and bacterial translocation - Improves mucosal barrier function - Reduces mechanical stress on the strictured segment - Corrects malnutrition (albumin, micronutrients) — critical pre-operative optimization if surgery is later needed 3. **Success rate:** Approximately **30–40%** of patients achieve meaningful symptomatic improvement; complete stricture resolution is uncommon, but EEN serves as an important bridge to surgery and corrects nutritional deficits *(Harrison's Principles of Internal Medicine, 21e, Ch. 296)* 4. **Duration:** 6–8 weeks minimum **Clinical Pearl:** EEN is particularly effective in **pediatric Crohn's disease** and in patients with **fibrostenosing phenotype** where active inflammation is minimal. It also optimizes the patient nutritionally before any potential surgical intervention, reducing perioperative risk. ### Step 2: Reassess After 6–8 Weeks - **Symptom improvement + nutritional recovery** → continue maintenance therapy, consider endoscopic balloon dilation for short strictures - **No improvement or worsening obstruction** → ileocecal resection ### When Surgery Is Indicated - Failure of nutritional/medical therapy - Recurrent or complete obstruction - Perforation, abscess, or fistulization - Intractable symptoms affecting quality of life **Mnemonic: STRICTURE management = STEN** - **S**tricture confirmed on imaging - **T**rial of enteral nutrition (EEN) first - **E**valuate response at 6–8 weeks - **N**ext step: surgery if no improvement ## Why Other Options Are Incorrect ### Option A: High-Dose IV Methylprednisolone - Corticosteroids target **active mucosal inflammation**, not fibrosis - This patient's low CRP argues against significant active inflammation - Steroids do not reverse established fibrosis or stricture - Prolonged steroid use causes bone loss, infection risk, and metabolic complications - **Not appropriate as first-line for fibrostenosing phenotype** ### Option B: Urgent Ileocecal Resection - Surgery is **not first-line** for stricturing disease without complete obstruction, perforation, or abscess - This patient is hemodynamically stable with no sepsis — a nutritional trial is appropriate first - Premature surgery increases risk of short bowel syndrome - Recurrence rate after resection: ~50% at 5 years, ~80% at 10 years *(Robbins & Cotran Pathologic Basis of Disease, 10e, Ch. 17)* ### Option C: Increase Azathioprine + Add Infliximab - A common trap: biologics (TNF-α inhibitors) are effective for **inflammatory Crohn's disease**, NOT fibrostenosing disease - Low CRP indicates minimal active inflammation - TNF-α inhibitors do not reverse fibrosis or prevent stricture progression - Escalating immunosuppression without addressing nutrition is incorrect management [cite:Harrison 21e Ch 296; Robbins 10e Ch 17]